Market Overview

UPDATE: Credit Suisse Downgrades PDL Biopharma to Underperform on Valuation

Related PDLI
PDL BioPharma Announces Developments Related to LENSAR Debt Investment, Will Receive ~$12.5 In Alphaeon Common Stock
PDL BioPharma Announces Developments Related to LENSAR Debt Investment

Credit Suisse downgraded PDL BioPharma, Inc. (NASDAQ: PDLI) from Neutral to Underperform and lowered the price target from $6.50 to $6.00.

Credit Suisse commented, "We are downgrading PDLI to Underperform to balance our portfolio of ratings and reflect our view that the stock price is above our fair value calculation. Unlike other names we cover, PDLI lacks significant optionality as new products deliver a finite and relatively short revenue stream. The high regular dividend, potential for special dividends, and a lack of visible downside triggers make PDLI an "expensive" short, which is not our recommendation."

PDL Biopharma closed at $7.42 on Monday.

Latest Ratings for PDLI

May 2013Piper JaffrayInitiates Coverage onNeutral
Mar 2013JP MorganMaintainsNeutral
Jan 2013Credit SuisseDowngradesNeutralUnderperform

View More Analyst Ratings for PDLI
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (PDLI)

View Comments and Join the Discussion!

Get Benzinga's Newsletters